ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.

ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.

Item
http://www.wikidata.org/entity/Q38942453
Current challenges and novel treatment strategies in double hit lymphomasThe role of BH3-mimetic drugs in the treatment of pediatric hepatoblastomaMotif mediated protein-protein interactions as drug targetsTransformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RCDevelopment of venetoclax for therapy of lymphoid malignancies.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.New targeted therapies for malignant lymphoma based on molecular heterogeneity.BET-inhibitors as sensitizers for BH3-mimetics.Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review.BCL2 inhibition in double hit lymphoma.BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma.Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with / and / gene arrangements and potential molecular targeted therapiesDual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
P2860

ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.

Item
http://www.wikidata.org/entity/Q38942453
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
ABT-199, a BH3 mimetic that sp ...... n "double hit" lymphoma cells.
@en
type
label
ABT-199, a BH3 mimetic that sp ...... n "double hit" lymphoma cells.
@en
prefLabel
ABT-199, a BH3 mimetic that sp ...... n "double hit" lymphoma cells.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
ABT-199, a BH3 mimetic that sp ...... n "double hit" lymphoma cells.
@en
P2093
P304
P31
P356
10.3109/10428194.2014.981172
P433
P478
P577
P698